

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-151) TISLELIZUMAB

PRONUNCIATION tis" le liz' ue mab

THERAPEUTIC CLAIM Antineoplastic

## CHEMICAL NAMES

1. Immunoglobulin G4, anti-(human programmed cell death protein 1) synthetic clone 317-4B6 heavy chain VH fragment fusion protein with human  $\gamma$ 4 chain clone mut10 effector/constant domain fragment, disulfide with anti-(human programmed cell death protein 1) synthetic clone 317-4B6 light chain VL fragment fusion protein with human  $\kappa$  chain constant region fragment, dimer
2. Immunoglobulin G4-kappa, anti-[Homo sapiens PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody; gamma4 heavy chain (1-445) [humanized VH (Homo sapiens IGHV4-59\*01 (88.70%) - (IGHD) -IGHJ3\*01 M123>T (113)) [8.7.12] (1-118) -Homo sapiens IGHG4\*01 (CH1 (119-216), hinge S10>P (226) (217-228), CH2 E1.4>P (231), F1.3>V (232), L1.2>A (233), D27>A (263) (229-338), CH3 R88>K (407) (339-443), CHS (444-445)) (119-445)], (132-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV4-1\*01 (81.20%) -IGKJ2\*01) [6.3.9] (1'-107') -Homo sapiens IGKC\*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (224-224":227-227")-bisdisulfide

## STRUCTURAL FORMULA

### Heavy chain

QVQLQESGPG	LVKPSETLSL	TCTVSGFSLT	SYGVHWIRQP	PGKGLEWIGV	50
IYADGSTNYN	PSLKSRTVIS	KDTSKNQVSL	KLSSVTAADT	AVYYCARAYG	100
NYWYIDVWGQ	GTTVTVSSAS	TKGPSVFPLA	PCSRSTSEST	AALGCLVKDY	150
FPEPVTVSWN	SGALTSGVHT	FPAVLQSSGL	YSLSSVVTVP	SSSLGTRKTYT	200
CNVDHKPSNT	KVDRKRVESKY	GPPCPPCPAP	PVAGGSPVFL	FPPKPKDTLM	250
ISRTPEVTCV	VVAVSQEDPE	VQFNWYVDGV	EVHNAKTKPR	EEQFNSTYRV	300
VSVLTVVHQD	WLNKEYKCK	VSNKGLPSSI	EKTISKAKGQ	PREPQVYTLP	350
PSQEEMTKNQ	VSLTCLVKGF	YPSDIAVEWE	SNGQPENNYK	TTPPVLDSDG	400
SFFLYSKLTV	DKSRWQEGNV	FSCSVMHEAL	HNHYTQKSLS	LSLGK	445

### Light chain

DIVMTQSPDS	LAVSLGERAT	INCKSSESVS	NDVAWYQQKP	GQPPKLLINY	50'
AFHRFTGVPD	RFSGSGYGTD	FLLTISSLQA	EDVAVYYCHQ	AYSSPYTFGQ	100'
GTKLEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYLSSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

### Disulfide bridges

22-95	22''-95''	23—88'	23'''-88'''	132-214'	132''-214'''	134'-194'	134'''-194'''
145-201	145''-201''	224-224''	227-227''	259-319	259''-319''	365-423	365'''-423'''

### Glycosylation sites (N)

Asn295 Asn295''

## MOLECULAR FORMULA

C<sub>6410</sub>H<sub>9916</sub>N<sub>1686</sub>O<sub>2009</sub>S<sub>40</sub>

MOLECULAR WEIGHT	144.0 kDa
TRADEMARK	None as yet
SPONSOR	BeiGene USA, Inc.
CODE DESIGNATIONS	BGB-A317
<u>CAS</u> REGISTRY NUMBER	1858168-59-8
UNII	0KVO411B3N
WHO NUMBER	10553

gbk